SCHEMBL4516982

SCHEMBL4516982

O=C1C(CCc2ccccc2Cl)CCN1C1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.56
ROCK2 O75116 2/20 0.49
LMNA P02545 1/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
KCNH2 Q12809 1/20 0.39
TSHR P16473 3/20 0.39
ALOX15 P16050 1/20 0.39
CXCR4 P61073 1/20 0.39
CHRM3 P20309 1/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3554597 0.87 HSD11B1 (0.67) HSD11B1ROCK2LMNAALDH1A1MAPT
SCHEMBL3878986 0.81 HSD11B1 (0.74) HSD11B1LMNAALDH1A1MEN1KMT2A
SCHEMBL5507832 0.79 CNR1 (0.43) HSD11B1ROCK2
SCHEMBL3553955 0.77 HSD11B1 (0.64) HSD11B1LMNAALDH1A1MAPTMEN1
SCHEMBL3882511 0.76 HSD11B1 (0.71) HSD11B1LMNAALDH1A1CHRM3MEN1
SCHEMBL4505216 0.76 ALDH1A1 (0.48) LMNAALDH1A1MEN1POLBKMT2A
SCHEMBL2999410 0.76 HSD11B1 (0.65) HSD11B1LMNAALDH1A1MEN1POLB
SCHEMBL4525789 0.75 HSD11B1 (0.51) HSD11B1ROCK2LMNAALDH1A1MAPT
SCHEMBL4698733 0.75 HSD11B1 (0.61) HSD11B1ROCK2LMNAALDH1A1MEN1
SCHEMBL3544238 0.75 HSD11B1 (0.60) HSD11B1LMNAALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885ROCK2 2463/4885LMNA 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.